Logo image of CPIX

CUMBERLAND PHARMACEUTICALS (CPIX) Stock Fundamental Analysis

NASDAQ:CPIX - US2307701092 - Common Stock

3.4 USD
0 (0%)
Last: 8/27/2025, 8:00:01 PM
Fundamental Rating

4

Taking everything into account, CPIX scores 4 out of 10 in our fundamental rating. CPIX was compared to 193 industry peers in the Pharmaceuticals industry. While CPIX seems to be doing ok healthwise, there are quite some concerns on its profitability. CPIX is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year CPIX was profitable.
CPIX had a positive operating cash flow in the past year.
In the past 5 years CPIX always reported negative net income.
CPIX had a positive operating cash flow in 4 of the past 5 years.
CPIX Yearly Net Income VS EBIT VS OCF VS FCFCPIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

1.2 Ratios

CPIX has a Return On Assets of -4.32%. This is in the better half of the industry: CPIX outperforms 71.50% of its industry peers.
CPIX has a Return On Equity of -10.47%. This is in the better half of the industry: CPIX outperforms 74.61% of its industry peers.
Industry RankSector Rank
ROA -4.32%
ROE -10.47%
ROIC N/A
ROA(3y)-7.42%
ROA(5y)-5.97%
ROE(3y)-21.64%
ROE(5y)-16.04%
ROIC(3y)N/A
ROIC(5y)N/A
CPIX Yearly ROA, ROE, ROICCPIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5 -10 -15 -20 -25

1.3 Margins

With an excellent Gross Margin value of 83.99%, CPIX belongs to the best of the industry, outperforming 90.16% of the companies in the same industry.
CPIX's Gross Margin has been stable in the last couple of years.
CPIX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.04%
CPIX Yearly Profit, Operating, Gross MarginsCPIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

5

2. Health

2.1 Basic Checks

CPIX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CPIX has less shares outstanding
The number of shares outstanding for CPIX has been reduced compared to 5 years ago.
CPIX has a worse debt/assets ratio than last year.
CPIX Yearly Shares OutstandingCPIX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
CPIX Yearly Total Debt VS Total AssetsCPIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of 0.88, we must say that CPIX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.88, CPIX perfoms like the industry average, outperforming 57.51% of the companies in the same industry.
The Debt to FCF ratio of CPIX is 0.75, which is an excellent value as it means it would take CPIX, only 0.75 years of fcf income to pay off all of its debts.
CPIX's Debt to FCF ratio of 0.75 is amongst the best of the industry. CPIX outperforms 94.82% of its industry peers.
A Debt/Equity ratio of 0.19 indicates that CPIX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.19, CPIX is in line with its industry, outperforming 47.15% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 0.75
Altman-Z 0.88
ROIC/WACCN/A
WACC9.49%
CPIX Yearly LT Debt VS Equity VS FCFCPIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 1.30 indicates that CPIX should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.30, CPIX is doing worse than 73.06% of the companies in the same industry.
CPIX has a Quick Ratio of 1.17. This is a normal value and indicates that CPIX is financially healthy and should not expect problems in meeting its short term obligations.
CPIX has a worse Quick ratio (1.17) than 69.43% of its industry peers.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 1.17
CPIX Yearly Current Assets VS Current LiabilitesCPIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 207.69% over the past year.
Looking at the last year, CPIX shows a quite strong growth in Revenue. The Revenue has grown by 11.34% in the last year.
Measured over the past years, CPIX shows a small growth in Revenue. The Revenue has been growing by 1.95% on average per year.
EPS 1Y (TTM)207.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)11.34%
Revenue growth 3Y1.71%
Revenue growth 5Y1.95%
Sales Q2Q%10.05%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CPIX Yearly Revenue VS EstimatesCPIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CPIX Yearly EPS VS EstimatesCPIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2018 2019 2020 2023 2024 0 0.2 -0.2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 24.29, CPIX is valued on the expensive side.
CPIX's Price/Earnings ratio is rather cheap when compared to the industry. CPIX is cheaper than 80.83% of the companies in the same industry.
When comparing the Price/Earnings ratio of CPIX to the average of the S&P500 Index (27.14), we can say CPIX is valued inline with the index average.
Industry RankSector Rank
PE 24.29
Fwd PE N/A
CPIX Price Earnings VS Forward Price EarningsCPIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CPIX is valued cheaper than 83.94% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CPIX is valued cheaper than 93.26% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.33
EV/EBITDA 14.16
CPIX Per share dataCPIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CPIX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CUMBERLAND PHARMACEUTICALS

NASDAQ:CPIX (8/27/2025, 8:00:01 PM)

3.4

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-05 2025-11-05
Inst Owners28.76%
Inst Owner Change-13.97%
Ins Owners3.46%
Ins Owner Change0%
Market Cap50.86M
Analysts43.33
Price TargetN/A
Short Float %0.24%
Short Ratio0.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 24.29
Fwd PE N/A
P/S 1.21
P/FCF 7.33
P/OCF 7.14
P/B 1.82
P/tB 4.59
EV/EBITDA 14.16
EPS(TTM)0.14
EY4.12%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.46
FCFY13.65%
OCF(TTM)0.48
OCFY14%
SpS2.81
BVpS1.87
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.32%
ROE -10.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.99%
FCFM 16.5%
ROA(3y)-7.42%
ROA(5y)-5.97%
ROE(3y)-21.64%
ROE(5y)-16.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.04%
F-Score7
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 0.75
Debt/EBITDA 1.85
Cap/Depr 3.11%
Cap/Sales 0.43%
Interest Coverage N/A
Cash Conversion 251.96%
Profit Quality N/A
Current Ratio 1.3
Quick Ratio 1.17
Altman-Z 0.88
F-Score7
WACC9.49%
ROIC/WACCN/A
Cap/Depr(3y)16.58%
Cap/Depr(5y)20.37%
Cap/Sales(3y)2.19%
Cap/Sales(5y)2.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)207.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)11.34%
Revenue growth 3Y1.71%
Revenue growth 5Y1.95%
Sales Q2Q%10.05%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y60.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-12.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.42%
OCF growth 3YN/A
OCF growth 5YN/A